Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.

Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.

Novavax, Inc. (Nasdaq: NVAX), a leading company in protein-based vaccines, has announced that its latest COVID-19 vaccine, the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This authorization permits its use for active immunization to prevent COVID-19 in individuals aged 12 and […]

Is US facing new COVID-19 nightmare? KP.2 variant pushes hospitalization rates to record levels

Is US facing new COVID-19 nightmare? KP.2 variant pushes hospitalization rates to record levels

The United States is grappling with the most severe COVID-19 surge since 2022, characterised by a sharp increase in hospitalisation rates and intensified viral activity. Recent data from the Centers for Disease Control and Prevention (CDC) highlights a troubling rise in hospitalisation rates, which have surged from one person per 100,000 in May to four […]

Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial

Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial

Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the American biotech company, the recombinant nanoparticle protein-based vaccine has overall shown 80% efficacy overall at a time when the Delta variant was the main circulating strain in the US. The […]

Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine development company is carrying out the late-stage trial in the UK in partnership with the UK government’s Vaccines Taskforce. The phase 3 trial of NVX-CoV2373 will aim to enroll and […]

Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]

Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB

Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB

Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance for NVX-CoV2373, the former’s COVID-19 vaccine candidate. FUJIFILM Diosynth Biotechnologies’ facility in Morrisville, North Carolina has started production of the first batch of NVX-CoV2373. The arrangement between the two firms […]